Upgrade of Evonik’s MetAMINO® production in Singapore reaches first milestone

25 January 2024

Evonik’s MetAMINO® (DL-methionine) production facility upgrade at its Singapore site is progressing on schedule. After a three-month shutdown in the fourth quarter of 2023, MetAMINO® production on Jurong Island is again running at full capacity. A shutdown of the second MetAMINO® production plant will be necessary in Q2/2024.

The modification is part of the implementation of Evonik’s methionine asset strategy to safeguard long-term sustainable global supply security based on its best-in-class production hubs in three parts of the world: Singapore, Mobile (Alabama, USA), and Antwerp (Belgium).

“As the only global methionine provider, we are able to offer our customers worldwide supply security. Beyond that, we constantly seek to raise the sustainability of our production plants,” says Dr. Dirk Hoehler, head of the Essential Nutrition business at Evonik’s Animal Nutrition business line. For the ongoing upgrades in Singapore, another shutdown of one plant is needed in the second quarter since the necessary measures cannot be carried out during day-to-day operations.

The upgrade will improve the efficiency of the facility’s processes and reduce the product carbon footprint of MetAMINO® from the plants in Singapore by six percent (Scope 1+2+3).

The reduction of the carbon footprint results from several modifications: the use of green hydrogen, an intensive energy integration, and an innovative solution for improved circularity that recovers MetAMINO® and raw materials. The further reduction of the carbon footprint of MetAMINO® from Singapore also helps Evonik’s customers and partners along the food value chain reach their sustainability goals. Evonik has verified science-based targets to reduce emissions in line with a well-below 2°C warming pathway, and a long-term intention to raise its ambition to reach net-zero emissions by 2050.

MetAMINO® is used in livestock production to feed animals healthily, efficiently, and sustainably. With its science-based approach, the Animal Nutrition business line of Evonik develops products, services and system solutions that help supply a growing world population with healthy, high-quality and affordable animal protein. Animal Nutrition is part of Evonik's Nutrition & Care division and contributes significantly to the profitable growth of Nutrition & Care through its self-financing power.

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow.

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €4.24 billion in 2022 with about 5,700 employees.